| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the results of RESONATE™-2 (PCYC-1115), a Phase 3 clinical trial in which ibrutinib (IMBRUVICA®) significantly...
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition represent a...
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
Findings from an ongoing Phase IIa study to evaluate the safety and efficacy of investigational chimeric antigen receptor T cell (CART) therapy CTL019 in certain types of relapsed or refractory...
-
Dec 5, 2015Virtual Press Office and PR Newswire: General Trade show news
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxalta Incorporated (Baxalta) (NYSE: BXLT) today announced results from a new analysis of the pivotal Phase 3 trial, PERSIST-1,...
-
Dec 5, 2015Virtual Press Office and PR Newswire: General Trade show news
Amgen (NASDAQ:AMGN) today announced the presentation of new key data evaluating Kyprolis® (carfilzomib) -based regimens in patients with relapsed multiple myeloma. The data showed Kyprolis in...
